Tag: recovery trial

thromboprophylaxis

JC: Thromboprophylaxis on the ICU for COVID-19 patients. St Emlyn’s

The prevention of venous thromboembolism (VTE) has been a real concern in the management of hospitalised patients with COVID-19. We have previously discussed the role of prophylactic anticoagulation (thromboprophylaxis) for these patients as it was

February 2021 podcast

February 2021 Round Up Podcast. St Emlyn’s

Our regular podcast round up from February 2021. Iain and Simon highlight the key learning points from this month on the St Emlyn’s blog and podcast. Please remember to subscribe to the podcast on iTunes/Google

convalescent plasma

JC: Convalescent plasma (still) does not work in COVID-19. St Emlyn’s

The latest results on the use of convalescent plasma in Covid-19 are now out from the RECOVERY trial as a pre-print. As you know we have already covered the trial quite extensively and thus far

Colchicine

Colchicine does not improve mortality in COVID19. St Emlyn’s

This week the RECOVERY trial has released the first results from the Colchicine arm of the trial. We await the pre-print and the peer reviewed paper, but we are already very familiar with the trial

JC: Lopinavir/Ritonavir in the treatment of COVID-19

We have been following the RECOVERY trial closely over the last few months. It’s the largest RCT of therapeutics for COVID-19 in the world and it’s already shown that hydroxychloroquine and azithromycin don’t work in

azithromycin stemlyns covid-19

JC: Azithromycin in patients hospitalised with COVID-19

As we near the end of 2020, it is worth taking a moment to reflect on what a year it has been. At the beginning of the year we were first hearing about a respiratory

Tocilizumaybe? Immune modulation in COVID-19 @StEmlyns

I am sure many of you saw the breaking news on the BBC the other week, about a new wonderdrug to strengthen our defences against the tidal wave that is COVID19. This follows a press

Dexamethasone, COVID-19 and the RECOVERY trial. St Emlyn’s

We have previously covered the RECOVERY trial on St Emlyn’s noting that the first results out of this large pragmatic, adaptive design platform RCT showed no benefit to Hydroxychloroquine. A few weeks ago a press

Translate »